Thursday, 19 December 2013

Altered Spontaneous Brain Activity in Type 2 Diabetes: A Resting-State Functional MRI Study

The abnormalities of spontaneous brain activity reflected by ALFF and ReHo measurements in the absence of structural changes in T2DM patients may provide insights into the neurological pathophysiology underlying diabetes-associated cognitive decline (Diabetes)


Proinsulin-Transferrin Fusion Protein as a Novel Long-acting Insulin Analogue for the Inhibition of Hepatic Glucose Production

ProINS-Tf exhibited a slow, but sustained, in vivo hypoglycemic efficacy and long plasma half-life. Thus, ProINS-Tf fusion protein can potentially be administered as a prodrug with sustained Tf-mediated activation and selectivity in inhibiting hepatic glucose production (Diabetes)


Bristol-Myers Squibb - Sale of Its Diabetes Business

Bristol-Myers Squibb Company announce that it has signed an agreement to sell its global diabetes business that was part of its collaboration with AstraZeneca (Bristol-Myers Squibb)


Midlife type 2 diabetes and poor glycaemic control as risk factors for cognitive decline in early old age

The risk of accelerated cognitive decline in middle-aged patients with type 2 diabetes is dependent on both disease duration and glycaemic control (The Lancet Diabetes & Endocrinology)

No comments:

Post a Comment